These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 8823477)

  • 1. A phase II trial of VP-16, ifosfamide, cisplatin, vinblastine, and bleomycin in advanced germ-cell tumors.
    Blanke C; Loehrer PJ; Nichols CR; Einhorn LH
    Am J Clin Oncol; 1996 Oct; 19(5):487-91. PubMed ID: 8823477
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk-adapted chemotherapy of germ cell tumors with carboplatin, etoposide and bleomycin for low-risk and cisplatin, etoposide and ifosfamide for high-risk patients. A single-center study.
    Tscherry G; Jacky E; Jost LM; Stahel RA
    Oncology; 2000 Aug; 59(2):110-7. PubMed ID: 10971168
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term results of first-line sequential high-dose etoposide, ifosfamide, and cisplatin chemotherapy plus autologous stem cell support for patients with advanced metastatic germ cell cancer: an extended phase I/II study of the German Testicular Cancer Study Group.
    Schmoll HJ; Kollmannsberger C; Metzner B; Hartmann JT; Schleucher N; Schöffski P; Schleicher J; Rick O; Beyer J; Hossfeld D; Kanz L; Berdel WE; Andreesen R; Bokemeyer C;
    J Clin Oncol; 2003 Nov; 21(22):4083-91. PubMed ID: 14568987
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intensive induction-sequential chemotherapy with BOP/VIP-B compared with treatment with BEP/EP for poor-prognosis metastatic nonseminomatous germ cell tumor: a Randomized Medical Research Council/European Organization for Research and Treatment of Cancer study.
    Kaye SB; Mead GM; Fossa S; Cullen M; deWit R; Bodrogi I; van Groeningen C; Sylvester R; Collette L; Stenning S; De Prijck L; Lallemand E; deMulder P
    J Clin Oncol; 1998 Feb; 16(2):692-701. PubMed ID: 9469359
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Salvage therapy in recurrent germ cell cancer: ifosfamide and cisplatin plus either vinblastine or etoposide.
    Loehrer PJ; Lauer R; Roth BJ; Williams SD; Kalasinski LA; Einhorn LH
    Ann Intern Med; 1988 Oct; 109(7):540-6. PubMed ID: 2844110
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cisplatin, etoposide and either bleomycin or ifosfamide in the treatment of disseminated germ cell tumors: final analysis of an intergroup trial.
    Hinton S; Catalano PJ; Einhorn LH; Nichols CR; David Crawford E; Vogelzang N; Trump D; Loehrer PJ
    Cancer; 2003 Apr; 97(8):1869-75. PubMed ID: 12673712
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Modified cisplatin, etoposide (or vinblastine) and ifosfamide salvage therapy for male germ-cell tumors. Long-term results.
    Pizzocaro G; Salvioni R; Piva L; Faustini M; Nicolai N; Gianni L
    Ann Oncol; 1992 Mar; 3(3):211-6. PubMed ID: 1316779
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A randomized trial of cisplatin, vinblastine, and bleomycin versus vinblastine, cisplatin, and etoposide in the treatment of advanced germ cell tumors of the testis: a Southwest Oncology Group study.
    Wozniak AJ; Samson MK; Shah NT; Crawford ED; Ford CD; Altman SJ; Stephens RL; Natale RB; Bouroncle BA; Blumenstein BA
    J Clin Oncol; 1991 Jan; 9(1):70-6. PubMed ID: 1702148
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomized comparison of cisplatin and etoposide and either bleomycin or ifosfamide in treatment of advanced disseminated germ cell tumors: an Eastern Cooperative Oncology Group, Southwest Oncology Group, and Cancer and Leukemia Group B Study.
    Nichols CR; Catalano PJ; Crawford ED; Vogelzang NJ; Einhorn LH; Loehrer PJ
    J Clin Oncol; 1998 Apr; 16(4):1287-93. PubMed ID: 9552027
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cisplatin and ifosfamide with either vinblastine or etoposide as salvage therapy for refractory or relapsing germ cell tumor patients: the Institut Gustave Roussy experience.
    Farhat F; Culine S; Théodore C; Békradda M; Terrier-Lacombe MJ; Droz JP
    Cancer; 1996 Mar; 77(6):1193-7. PubMed ID: 8635143
    [TBL] [Abstract][Full Text] [Related]  

  • 11. BOMP/EPI intensive alternating chemotherapy for IGCCC poor-prognosis germ-cell tumors: the Spanish Germ-Cell Cancer Group experience (GG).
    Germà-Lluch JR; Garcia del Muro X; Tabernero JM; Sánchez M; Aparicio J; Alba E; Barnadas A
    Ann Oncol; 1999 Mar; 10(3):289-93. PubMed ID: 10355572
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tandem high dose chemotherapy with autologous bone marrow transplantation for initial relapse of testicular germ cell cancer.
    Broun ER; Nichols CR; Gize G; Cornetta K; Hromas RA; Schacht B; Einhorn LH
    Cancer; 1997 Apr; 79(8):1605-10. PubMed ID: 9118046
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Treatment of non-testicular germ cell tumors in children and adolescents with BEP and VIP: initial results of the MAKEI 89 therapy study].
    Göbel U; Bamberg M; Engert J; Gnekow AK; Haas HJ; Jürgens H; Kühl J; Lenard HG; Lumenta C; Niethammer D
    Klin Padiatr; 1991; 203(4):236-45. PubMed ID: 1719267
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vinblastine plus ifosfamide plus cisplatin as initial salvage therapy in recurrent germ cell tumor.
    Loehrer PJ; Gonin R; Nichols CR; Weathers T; Einhorn LH
    J Clin Oncol; 1998 Jul; 16(7):2500-4. PubMed ID: 9667270
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Early salvage therapy for germ cell cancer using high dose chemotherapy with autologous bone marrow support.
    Broun ER; Nichols CR; Turns M; Williams SD; Loehrer PJ; Roth BJ; Lazarus HM; Einhorn LH
    Cancer; 1994 Mar; 73(6):1716-20. PubMed ID: 7512438
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Salvage chemotherapy in refractory germ cell tumors with etoposide (VP-16) plus ifosfamide plus high-dose cisplatin. A VIhP regimen.
    Ghosn M; Droz JP; Theodore C; Pico JL; Baume D; Spielmann M; Ostronoff M; Moran A; Salloum E; Kramar A
    Cancer; 1988 Jul; 62(1):24-7. PubMed ID: 3133101
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alternating dose-dense chemotherapy in patients with high volume disseminated non-seminomatous germ cell tumours.
    Fizazi K; Prow DM; Do KA; Wang X; Finn L; Kim J; Daliani D; Papandreou CN; Tu SM; Millikan RE; Pagliaro LC; Logothetis CJ; Amato RJ
    Br J Cancer; 2002 May; 86(10):1555-60. PubMed ID: 12085204
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A prospective randomized phase III study in non-small-cell lung cancer comparing cisplatin, ifosfamide, vinblastine (VIP) versus cisplatin, ifosfamide and etoposide (VIP-16). Hellenic Co-Operative Oncology Group.
    Kosmidis P; Mylonakis N; Fountzilas G; Pavlidis N; Samantas E; Karabelis A; Kattis K; Skarlos D
    Ann Oncol; 1996 Jul; 7(5):517-20. PubMed ID: 8839908
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ifosfamide- and cisplatin-containing chemotherapy as first-line salvage therapy in germ cell tumors: response and survival.
    McCaffrey JA; Mazumdar M; Bajorin DF; Bosl GJ; Vlamis V; Motzer RJ
    J Clin Oncol; 1997 Jul; 15(7):2559-63. PubMed ID: 9215825
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of germ cell cancer with two cycles of high-dose ifosfamide, carboplatin, and etoposide with autologous stem-cell support.
    Margolin K; Doroshow JH; Ahn C; Hamasaki V; Leong L; Morgan R; Raschko J; Shibata S; Somlo G; Tetef M
    J Clin Oncol; 1996 Oct; 14(10):2631-7. PubMed ID: 8874321
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.